Hodgkin's Disease Clinical Trials

A listing of Hodgkin's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 388 clinical trials
Featured trial
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was established for each of the 2 compounds as a treatment option for adult participants with R/R …

btk inhibitor
chronic lymphocytic leukemia
cyclin d1
lymphoma
anti-cd20 antibody
  • 2 views
  • 09 Aug, 2022
  • 40 locations
Featured trial
A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).  

b-cell lymphoma
lymphomas
lymphoma
  • 95 views
  • 10 May, 2022
  • 2 locations
HD21 for Advanced Stages

Primary objective of the trial is to demonstrate non-inferior efficacy of six cycles of BrECADD compared to six cycles of escalated BEACOPP, each followed by radiotherapy to PET-positive residual lesions ≥2.5 cm, in terms of progression free survival (efficacy objective). If non-inferior efficacy can be shown, the co-primary objective is …

prednisone
lymphoma
vincristine
brentuximab
dacarbazine
  • 6 views
  • 11 Aug, 2022
  • 1 location
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

acalabrutinib
rituximab
bendamustine
cyclin d1
  • 1317 views
  • 11 Jul, 2022
  • 30 locations
Itacitinib + Everolimus in Hodgkin Lymphoma

This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).

neutrophil count
brentuximab
gonadotropin
refractory classical hodgkin lymphoma
measurable disease
  • 1 views
  • 27 Jul, 2022
  • 1 location
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

This phase II trial studies the side effects of doxorubicin hydrochloride, pembrolizumab, vinblastine, and dacarbazine in treating patients with classical Hodgkin lymphoma. Drugs used in

neutrophil count
pembrolizumab
growth factor
lymphoma
vinblastine
  • 0 views
  • 09 Apr, 2022
  • 1 location
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD7789 in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL

  • 0 views
  • 23 Jul, 2022
  • 2 locations
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR)

Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as …

classical hodgkin lymphoma
lymphoma
vinblastine
brentuximab
ejection fraction
  • 0 views
  • 09 Jun, 2022
  • 7 locations
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

This phase II trial studies how well anakinra works in decreasing the occurrence of cytokine release syndrome (CRS) and damage to the nerves (neurotoxicity) in patients with B-cell non-Hodgkin

cell therapy
  • 0 views
  • 09 Apr, 2022
  • 1 location
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Effectiveness of TRS005 in Patients With Relapsed or Refractory CD20-positive NHL.

positive B-cell non-Hodgkin's lymphoma were selected to evaluate the safety, tolerance (DLT, MTD) and pharmacokinetic (PK) characteristics of TRS005 by intravenous drip.

  • 0 views
  • 03 Jun, 2022
  • 1 location